In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes through) become one company, combining Recursion’s expertise in biology with Exscientia’s focus on chemistry.
Pre-Market: 5:05:46 a.m. EST Loading Chart for RXRX ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback